Radiation dose distribution in the teeth, maxilla, and mandible of patients with oropharyngeal and nasopharyngeal tumors who were treated with intensity-modulated radiotherapy

Head & Neck ◽  
2016 ◽  
Vol 38 (11) ◽  
pp. 1621-1627 ◽  
Author(s):  
Cláudia Joffily Parahyba ◽  
Fábio Ynoe Moraes ◽  
Pedro Augusto Minorim Ramos ◽  
Cecília Maria Kalil Haddad ◽  
João Luis Fernandes da Silva ◽  
...  
Keyword(s):  
Radiation Dose ◽  
Dose Distribution ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated ◽  
Nasopharyngeal Tumors ◽  
Maxilla And Mandible

scholarly journals Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Tzu-Hui Pao ◽  
Wei-Lun Chang ◽  
Nai-Jung Chiang ◽  
Jeffrey Shu-Ming Chang ◽  
Chia-Ying Lin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Dose ◽  
Adverse Events ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cumulative Incidence ◽  
Prognostic Significance ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated ◽  
Dose Volume ◽  
Cardiac Dose

Abstract Background The prognostic significance of cardiac radiation dose in esophageal cancer after definitive concurrent chemoradiotherapy (CCRT) remains largely unknown. We aimed to investigate the association between cardiac dose-volume parameters and overall survival (OS) in esophageal squamous cell carcinoma (ESCC) after definitive CCRT. Methods One hundred and twenty-one ESCC patients undergoing definitive CCRT with intensity modulated radiotherapy technique between 2008 and 2018 were reviewed. Cardiac dose-volume parameters were calculated. Survival of patients and cumulative incidence of adverse events were estimated by the Kaplan–Meier method and compared between groups by the log-rank test. The prognostic significance of cardiac dose-volume parameters was determined with multivariate Cox proportional hazards regression analysis. Results Median follow-up was 16.2 months (range, 4.3–109.3). Median OS was 18.4 months. Heart V5, V10, and V20 were independent prognostic factors of OS. Median OS was longer for patients with heart V5 ≤ 94.3% (24.7 vs. 16.3 months, p = 0.0025), heart V10 ≤ 86.4% (24.8 vs. 16.9 months, p = 0.0041), and heart V20 ≤ 76.9% (20.0 vs. 17.2 months, p = 0.047). Lower cumulative incidence of symptomatic cardiac adverse events was observed among patients with heart V5 ≤ 94.3% (p = 0.017), heart V10 ≤ 86.4% (p = 0.02), and heart V20 ≤ 76.9% (p = 0.0057). Patients without symptomatic cardiac adverse events had a higher 3-year OS rate (33.8% vs. 0%, p = 0.03). Conclusions Cardiac radiation dose inversely correlated with survival in ESCC after definitive CCRT. Radiation dose to the heart should be minimized.

scholarly journals Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy

2020 ◽  
Author(s):  
Tzu-Hui Pao ◽  
Wei-Lun Chang ◽  
Nai-Jung Chiang ◽  
Jeffrey Shu-Ming Chang ◽  
Chia-Ying Lin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Dose ◽  
Adverse Events ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cumulative Incidence ◽  
Prognostic Significance ◽  
Intensity Modulated Radiotherapy ◽  
Intensity Modulated ◽  
Dose Volume ◽  
Cardiac Dose

Abstract Background: The prognostic significance of cardiac radiation dose in esophageal cancer after definitive concurrent chemoradiotherapy (CCRT) remains largely unknown. We aimed to investigate the association between cardiac dose-volume parameters and overall survival (OS) in esophageal squamous cell carcinoma (ESCC) after definitive CCRT. Methods: One hundred and twenty-one ESCC patients undergoing definitive CCRT with intensity modulated radiotherapy technique between 2008 and 2018 were reviewed. Cardiac dose-volume parameters were calculated. Survival of patients and cumulative incidence of adverse events were estimated by the Kaplan–Meier method and compared between groups by the log-rank test. The prognostic significance of cardiac dose-volume parameters was determined with multivariate Cox proportional hazards regression analysis. Results: Median follow-up was 16.2 months (range, 4.3-109.3). Median OS was 18.4 months. Heart V5, V10, and V20 were independent prognostic factors of OS. Median OS was longer for patients with heart V5 ≤ 94.3% (24.7 vs. 16.3 months, p = 0.0025), heart V10 ≤ 86.4% (24.8 vs. 16.9 months, p = 0.0041), and heart V20 ≤ 76.9% (20.0 vs. 17.2 months, p = 0.047). Lower cumulative incidence of symptomatic cardiac adverse events was observed among patients with heart V5 ≤ 94.3% (p = 0.017), heart V10 ≤ 86.4% (p = 0.02), and heart V20 ≤ 76.9% (p = 0.0057). Patients without symptomatic cardiac adverse events had a higher 3-year OS rate (33.8% vs. 0%, p = 0.03). Conclusions: Cardiac radiation dose inversely correlated with survival in ESCC after definitive CCRT. Radiation dose to the heart should be minimized.

Treatment delivery, intensity-modulated radiotherapy, and image-guided radiotherapy

2013 ◽  
Author(s):  
Carl Rowbottom
Keyword(s):  
Radiation Dose ◽  
External Beam Radiotherapy ◽  
Intensity Modulated Radiotherapy ◽  
External Beam ◽  
Treatment Delivery ◽  
Image Guided Radiotherapy ◽  
Cancer Management ◽  
Image Guided ◽  
Intensity Modulated ◽  
Complex Processes

Chapter 3 discusses how successful delivery of external beam radiotherapy involves a number of complex processes beginning with the decision by the clinical oncologist to use radiotherapy as part of the patient’s cancer management, through the preparation and planning of the patient’s treatment, to the verification of the patient position and radiation dose delivered at the time of treatment.

Sign in / Sign up

Export Citation Format

Share Document